Youssef Bennani
Managing Partner @ CTI Life Sciences Fund
Youssef Bennani is a Series B investor at CTI Life Sciences Fund focused on Biotechnology and Pharmaceutical. Youssef Bennani is based out of Canada, and is the Managing Partner at CTI Life Sciences Fund and Board of Director at Aeovian Pharmaceuticals. Youssef previously served as the Chief Scientific Officer at adMare Bio Innovations. Youssef Bennani attended the Université de Montréal.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Youssef Bennani invests in
Stages Youssef Bennani invests in
Countries Youssef Bennani invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Pharmaceutical 2 (67%)
- Biopharma 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
Stage
- Series B 1 (33%)
- Series C 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M / Series B / Dec 16, 2025 | |
Oligon
|
Oligon company provides emerging biotechnology services developing a novel class of multimodal RNA therapeutics. They provide RNA oligonucleotide consultants, research associates, and research scientists. Their contact is done through phone and email. | $14M / Sep 23, 2025 | |
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M / Series C / Apr 16, 2025 |
Co-Investors
Abingworth
1 deal together
Advent Life Sciences
1 deal together
Apollo Health Ventures
1 deal together
Asahi Kasei Corporate Venture Capital
1 deal together
Chiesi Ventures
1 deal together
About CTI Life Sciences Fund
CTI Life Sciences, a Canadian venture firm makes venture capital investments in high quality emerging life sciences companies at the pre-clinical and clinical development stage in Canada and in the U.S. CTI Life Sciences currently manage $345 million of assets.
CTI Life Sciences Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Youssef Bennani
Managing Partner
|
|||
Jean-Francois Leprince
Managing Partner
|
|||
Ken Pastor
General Partner
|
|||
Shermaine Tilley
Managing Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Youssef Bennani invest in?
Youssef Bennani invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Youssef Bennani last invest?
The most recent investment recorded for Youssef Bennani closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
